Compare UPLD & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | SNTI |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 10.4M |
| IPO Year | 2014 | 2021 |
| Metric | UPLD | SNTI |
|---|---|---|
| Price | $3.34 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.75 | ★ $8.50 |
| AVG Volume (30 Days) | 32.0K | ★ 194.8K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.38 | ★ 77.31 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.95 | N/A |
| 52 Week Low | $0.50 | $0.29 |
| 52 Week High | $6.65 | $2.88 |
| Indicator | UPLD | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 29.59 |
| Support Level | $0.62 | N/A |
| Resistance Level | $5.65 | $0.40 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | -0.16 | 0.00 |
| Stochastic Oscillator | 3.45 | 7.74 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).